Site navigation

Navigation

Lung cancer (non-small-cell, first line) - gefitinib

Gefitinib for the first-line treatment of locally advanced or metastatic non small cell lung cancer

Status: In progress
Expected date of issue: June 2010
Wave: 10
Process: STA
Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Fay McCracken
Communications manager: Alice Law
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 24 September 2009
1st appraisal committee meeting: 07 January 2010
2nd appraisal committee meeting 04 March 2010
Top


 

Consultees and Commentators

Consultees Commentators

Manufacturers/sponsors

  • AstraZeneca (gefitinib)

Patient/carer groups

  • Macmillan Cancer Support
  • Roy Castle Lung Cancer Foundation

Professional groups

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)
  • Cancer Research UK
  • National Lung Cancer Forum for Nurses
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Kirklees PCT
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Abraxis Bioscience (paclitaxel)
  • Actavis Pharmaceuticals (paclitaxel, vinorelbine)
  • Bristol Myers Squibb (carboplatin, paclitaxel)
  • Eli Lilly (gemcitabine, pemetrexed)
  • Hospira (carboplatin, cisplatin, vinorelbine, paclitaxel)
  • Medac (paclitaxel, vinorelbine)
  • Pierre Fabre (vinorelbine)
  • Pharmacia (cisplatin)
  • Sanofi Aventis (docetaxel)

Relevant research groups

  • British Thoracic Oncology Group

Evidence Review Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated:   29 January 2010